INBX INHIBRX BIOSCIENCES INC revenue, earnings and financials
For the quarter ended June 30, 2026, INHIBRX BIOSCIENCES INC reported revenue of $0 (down 100.0% from a year earlier), net income of −$36.7M and diluted EPS of −$2.34; for the fiscal year ended December 2025 revenue was $1.30M, up 550.0% on the year before.
INBX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $1.30M, gross profit n/a, operating income −$135M, net income −$140M (margin -10773.5%), EPS −$9.04
- Fiscal year ended Dec 2024: revenue $200K, gross profit n/a, operating income −$331M, net income $1.69B (margin 843786.0%), EPS $112.62
- Fiscal year ended Dec 2023: revenue $1.80M, gross profit n/a, operating income −$219M, net income −$241M (margin -13408.9%), EPS −$20.48
INBX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $0 (down 100.0% year over year), net income −$36.7M, EPS −$2.34
- Quarter ended Mar 31, 2026: revenue n/a, net income −$33.4M, EPS −$2.15
- Quarter ended Dec 31, 2025 (from the annual report): revenue $0 (down 100.0% year over year), net income −$32.8M, EPS −$2.11
- Quarter ended Sep 30, 2025: revenue $0, net income −$35.3M, EPS −$2.28
- Quarter ended Jun 30, 2025: revenue $1.30M (up 1200.0% year over year), net income −$28.7M, EPS −$1.85
- Quarter ended Mar 31, 2025: revenue $0, net income −$43.3M, EPS −$2.80
- Quarter ended Dec 31, 2024 (from the annual report): revenue $100K, net income −$47.9M, EPS −$4.25
- Quarter ended Sep 30, 2024: revenue $0 (down 100.0% year over year), net income −$43.9M, EPS −$2.84
- Quarter ended Jun 30, 2024: revenue $100K (up 233.3% year over year), net income $1.86B, EPS $125.48
- Quarter ended Mar 31, 2024: revenue $0, net income −$78.7M, EPS −$5.77
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$93.6M, EPS n/a
- Quarter ended Sep 30, 2023: revenue $119K, net income −$51.8M, EPS −$4.39
- Quarter ended Jun 30, 2023: revenue $30.0K, net income −$47.1M, EPS −$4.31
- Quarter ended Mar 31, 2023: revenue n/a, net income −$48.9M, EPS n/a
INBX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$130M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$194M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$193M, share buybacks n/a
INBX balance sheet
- Jun 30, 2026: cash $133M, total assets $154M, total liabilities $207M, shareholders' equity −$53.0M, long-term debt $176M
- Mar 31, 2026: cash $162M, total assets $184M, total liabilities $205M, shareholders' equity −$21.0M, long-term debt $175M
- Dec 31, 2025: cash $124M, total assets $146M, total liabilities $138M, shareholders' equity $7.99M, long-term debt $101M
- Sep 30, 2025: cash $153M, total assets $177M, total liabilities $141M, shareholders' equity $36.8M, long-term debt $99.9M
- Jun 30, 2025: cash $187M, total assets $212M, total liabilities $144M, shareholders' equity $68.6M, long-term debt $99.3M
- Mar 31, 2025: cash $217M, total assets $243M, total liabilities $148M, shareholders' equity $94.4M, long-term debt $98.7M
- Dec 31, 2024: cash $153M, total assets $181M, total liabilities $47.2M, shareholders' equity $134M, long-term debt $0
- Sep 30, 2024: cash $196M, total assets $223M, total liabilities $44.1M, shareholders' equity $178M, long-term debt $0
What is INBX's revenue?
INHIBRX BIOSCIENCES INC reported $1.30M of revenue for the fiscal year ended December 2025.
Is INBX profitable?
No. INHIBRX BIOSCIENCES INC lost $138M over the last four quarters.
What is INBX's EPS?
Diluted earnings per share over the last four quarters were −$8.88; −$2.34 in the latest quarter.